The Effect of Sujok Therapy on Urinary Incontinence and Quality of Life in Postmenopausal Women

April 22, 2025 updated by: Gülçin NACAR, Inonu University
This study aims to investigate the effect of Su Jok therapy, a complementary medicine practice, on urinary incontinence and quality of life among postmenopausal women. A total of 120 participants will be included in the study, with 60 in the intervention group and 60 in the control group. Participants in the intervention group will receive Su Jok seed therapy applied to the hand reflex points corresponding to the bladder. The therapy will be administered by the researcher and then taught to the participants, who will continue the application for 15 days. Assessments will be conducted at baseline, day 15, and day 30 using validated questionnaires.

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

120

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey
    • Malatya
      • Battalgazi̇, Malatya, Turkey, 44280
        • Inonu University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

Women under 65 years of age in the postmenopausal period, Literate, No speech or communication impairment

Exclusion Criteria:

Use of diuretics

Presence of nephrotic syndrome

Diagnosis of diabetes or hypertension

Symptoms of urinary tract infection

Diagnosis of psychiatric illness

History of urinary tract surgery

Diagnosed urinary prolapse

Failure to complete the intervention

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: Control
standard care
Experimental: Intervention
Participants in the intervention group will receive seed therapy using apple seeds applied to specific hand points corresponding to the bladder area.
Other: Sujok therapy
Participants in the intervention group will receive seed therapy using apple seeds applied to specific hand points corresponding to the bladder area.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in urinary incontinence symptoms measured by the International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF)
Time Frame: At baseline, 15 days and 30 days after intervention

Description: The ICIQ-SF is a 4-item questionnaire used to evaluate the severity and impact of urinary incontinence.

Scoring: Scores range from 0 to 21, with higher scores indicating more severe urinary incontinence.

Unit of Measure: Points on a scale
At baseline, 15 days and 30 days after intervention
Change in quality of life measured by the Incontinence Quality of Life Scale (I-QOL)
Time Frame: At baseline, 15 days and 30 days after intervention

Description: The I-QOL assesses quality of life, including behavioral limitation, psychosocial impact, and social isolation, in postmenopausal women with urinary incontinence.

Scoring: Domain scores range from 0 to 100, where higher scores represent a poorer quality of life.

Unit of Measure: Total score (0-100)
At baseline, 15 days and 30 days after intervention

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Inonu University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 30, 2025

Primary Completion (Estimated)

July 30, 2025

Study Completion (Estimated)

July 30, 2025

Study Registration Dates

First Submitted

April 11, 2025

First Submitted That Met QC Criteria

April 22, 2025

First Posted (Actual)

April 30, 2025

Study Record Updates

Last Update Posted (Actual)

April 30, 2025

Last Update Submitted That Met QC Criteria

April 22, 2025

Last Verified

April 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2024/5494

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Postmenopause

Clinical Trials on Sujok therapy

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bahamas

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe